AFP and hepatocellular carcinoma: However, our findings suggest that in clinical practice bulevirtide may benefit and be proposed to patients with a lower MELD score (< 20) or those needing MELD exceptions, such as those with refractory ascites or untreatable HCC with AFP score ≤ 2 and MELD < 20, who face delays in accessing LT.